We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ALK-Abello A/S (ALK B) DKK0.5 B

Sell:123.70 DKK Buy:123.90 DKK Change: 2.30 DKK (1.82%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:123.70 DKK
Buy:123.90 DKK
Change: 2.30 DKK (1.82%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:123.70 DKK
Buy:123.90 DKK
Change: 2.30 DKK (1.82%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Contact details

Address:
Boege Alle 6-8
HOERSHOLM
2970
Denmark
Telephone:
+45 (45) 747576
Website:
https://www.alk.net/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALK B
ISIN:
DK0061802139
Market cap:
25.56 billion DKK
Shares in issue:
221.19 million
Sector:
Pharmaceuticals
Exchange:
Copenhagen Stock Exchange
Country:
Denmark
Currency:
Danish Krone
Indices:
n/a

Key personnel

  • Peter Halling
    President, Chief Executive Officer
  • Lene Skole- Soerensen
    Vice Chairman of the Board
  • Claus Solje
    Executive Vice President, Chief Financial Officer
  • Henriette Mersebach
    Executive Vice President - Research and Development
  • Soeren Niegel
    Executive Vice President - Commercial Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.